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Abstract Article Info 
Introduction: Nasopharyngeal carcinoma (NPC) is a squamous cell carcinoma of the mucosal nasopharynx with 
a unique geographical distribution which particularly prevalent in the east and southeast Asia. While 
nasopharyngeal carcinoma is a highly radiosensitive tumor, chemotherapy is added to enhance the effect of 
treatment. The therapeutic side effect is one of many factors that need to be considered when choosing the 
treatment method. Therefore, this study is conducted to address the side effect of neoadjuvant chemotherapy. 
Objective: This study is conducted to address the side effect of neoadjuvant chemotherapy. 
Methods: This study was a retrospective cohort study with total sampling method of all NPC patients in Hasan 
Sadikin General Hospital 2015-2019 period. 
Results: From a total of 247 subjects, NPC occurred in 180 men (72.87%). The most widely used regimen was 
Cisplatin + 5FU which is used in 187 patients (75.70%). There were several side effects caused by NPC 
chemotherapy including vomiting, nausea, fatigue, weight loss, dermatitis, stomatitis, hepatotoxicity, ototoxic, 
diarrhea, leucopenia, neutropenia, thrombocytopenia, and anemia. 
Conclusion: The most common side effect of cisplatin+5FU were ototoxicity therefore, audiometric 
examination both before and after administration of chemotherapy. Laboratory examination was needed for the 
administration of carboplatin+paclitaxel to monitor the side effects of neutropenia. 
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Nasopharyngeal carcinoma (NPC) is a squamous cell carcinoma 
(SCC) arising from the mucosal surface of the nasopharynx [1]. It is 
characterized by a geographical distribution which particularly prevalent 
in the east and southeast Asia [2]. Generally, the incidence in the world 
less than 1 per 100,000 person-years [3]. More than 80% of NPC patients 
are in Asia, with 71% of new NPC cases are recorded in East and 
Southeast Asia [4]. In the endemic population, NPC risk factors Epstein-
Barr virus (EBV) infection, environmental factors, such as the high intake 
of foods that rich in nitrosamines (preserved foods and salted fish), 
smoking, and genetic predisposition [3]. 
In 2012, an amount of 86,691 cases and 50,831 deaths of NPC had 
been documented in the world with sex ratio (male to female) of NPC risk 
about 2:36 and sex ratio (male to female) of NPC deaths about 2:37. The 
highest number of NPC cases was seen in five countries, such as China, 
Indonesia, Vietnam, India, and Malaysia [5]. In Indonesia, NPC are the 
fourth most common tumor after cervical cancer, breast cancer, and skin 
cancer and the most common malignancy in the head and neck [6].  It is 
a major burden in Indonesia, with 15,000 new cases a year [7]. 
While NPC is a highly radiosensitive tumor, chemotherapy is added 
to enhance the effect of radiation in locally advanced nasopharyngeal 
cancer because 70% of patients present with locally advanced stage and 
5-year survival with RT alone are poor [8]. Nasopharyngeal carcinoma 
has been considered to be not only radiosensitive but also chemo-
sensitive and has shown a high response rate to various 
chemotherapeutic agents [9]. 
Many factors need to be addressed in order to choose a treatment 
method, such as cancer itself, chemosensitivity or chemoresistance, cell 
population, growth cycle, the body's immune system, and therapeutic side 
effects [10]. Chemotherapy is defined as the application of chemicals or 
drugs to kill cancer cells, and its effects are systemic [11]. There are three 
main ways of combining systemic chemotherapy and radiotherapy; the 
classic combination ways include the induction (or neoadjuvant) 
chemotherapy before definitive radiotherapy and the adjuvant 
chemotherapy following definitive radiotherapy [12]. 
Neoadjuvant chemotherapy is defined as any chemotherapy regimen 
received prior to concurrent chemoradiotherapy [13]. Neoadjuvant 
chemotherapy agents commonly consist of platinum-based in 
combination with one of the following drugs: 5-fluorouracil, gemcitabine, 
paclitaxel, and docetaxel. Other drugs such as capecitabine, irinotecan, 
doxorubicin, vinorelbine, and oxaliplatin can also be used alone or in 
combination [14].  
A study shows that neoadjuvant chemotherapy plays an important 
role in distant control or delaying distant metastasis [12]. Some studies 
also indicated that neoadjuvant chemotherapy docetaxel-cisplatin, 
followed by concurrent chemoradiotherapy (CCRT), had improved 
overall survival than CCRT alone in stage III to IVB NPC patients [15]. 
Nausea and vomiting, myelosuppression, anemia, and renal 
impairment are common in patients receiving chemotherapy regimens 
[14]. The therapeutic side effect was one of many factors that need to be 
considered when choosing a treatment method [10]. Therefore, this study 
is conducted to address the side effect of neoadjuvant chemotherapy. 
2. MATERIALS AND METHODS  
This is a retrospective cohort study conducted in June 2020. The 
subjects of this study were patients with NPC that has been treated with 
neoadjuvant chemotherapies in Hasan Sadikin Hospital 2015-2019 
period. The data was taken from medical records with a total sampling 
method. The subjects of this study were NPC patients who underwent 
three cycles of chemotherapy to complete. Patients who have previously 
undergone a cycle of chemotherapy but are required to repeat the cycle 
were excluded. The data taken from medical records are patients 
characteristics, the regiment of neoadjuvant chemotherapy, and the side 
effects after each cycle. 
3. RESULTS 
During the period of the study, there were 247 subjects, with 180 
(72.87%) were male and 67 (27.13%) were female. Most of the subjects 
were age 35-49 years. The distribution of subjects’ characteristic is 
presented in table 1. 







Table 1. Characteristic of the Subjects 
Table 2 shows that there were 2 regiments of neoadjuvant chemotherapy 
has been used in this study, with the most regiment used was Cisplatin+5FU. 
Table 2. Regiments 
Table 3 shows all of the side effects from neoadjuvant chemotherapy 
used was Cisplatin+5FU in NPC patients. 
Table 3. Side effects of Cisplatin+5FU 
Table 4 shows all of the side effects from neoadjuvant chemotherapy 
used was Carboplatin+Paclitaxel in NPC patients. 
Table 4. Side effects of Carboplatin+Paclitaxel 
4. DISCUSSIONS 
A study conducted in 2018 found that in Indonesia, NPC is a relatively 
high incidence and more common in males [16]. Different lifestyle habits 
between men and women (e.g., tobacco consumption) or biological 
differences may be the cause [17]. In table 1, the data shows that many NPCs 
occur at the age of 35-49 years. This contrasts with a study in 2016, which 
stated that the peak age of incidence is between 50 and 60 years [18]  
Table 1 shows that the most common stage of the cases was stadium 3 
(52.22%) and 4 (32.38%). The most common histopathologic characteristic 
of the cases was type III (74.49%). This is supported by a study which also 
stated that the most common histopathologic characteristic of the cases was 
non-keratinizing undifferentiated carcinoma [19]. 
Evaluation after giving chemotherapy in the first cycle showed that 
fatigue was the most common side effect experienced by patients with a total 
of 137 (55.46%). This is supported by a study that states that fatigue is found 
in 52.4% of patients and is the most side effect in NPC patients [20].  
The number of patients who experience side effects such as vomiting, 
nausea, fatigue, dermatitis, stomatitis, and diarrhea decreases from the first 
to the third cycle. This decrease may be due to the body's ability to adapt to 
the amount of chemotherapy received. Meanwhile, side effects such as 
weight loss, ototoxic, leucopenia, neutropenia, thrombocytopenia, and 
anemia actually show an increase as the chemotherapy cycle progresses. 
The most common side effects of cisplatin+5FU in the third cycle were 
ototoxicity. The mechanistic basis for ototoxicity induced by cisplatin is not 
fully understood yet, but cisplatin is known to damage the organ of Corti, 
the spiral ganglion, and the stria vascularis as primary targets. 
Administration of antioxidants plays an important role in preventing 
ototoxicity due to cisplatin chemotherapy, pure tone audiometry should be 
examined prior to chemotherapy, and after chemotherapy [21]. The most 
common side effects of carboplatin+paclitaxel in the third cycle were 
leucopenia. Therefore, laboratory examination was needed to be carried out 
before and after chemo carboplatin. 
5. CONCLUSION 
The most common side effect of cisplatin+5FU were ototoxicity, 
therefore an audiometric examination both before and after administration 
of chemotherapy. Laboratory examination is needed for the administration 
of carboplatin + paclitaxel to monitor the side effects of neutropenia. 
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      35-49 
      50-64 
      >65 
Stage 
      1 
      2 
      3 
      4 
Histopathology (WHO Classification) 
      Type I – Squamous cell carcinoma 
      Type II – Keratinizing undifferentiated carcinoma 





























Total 247 100 







Total 247 100 
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